
    
      This trial included 80 vitamin B12-deficient T1DM patients with nephropathy, despite oral
      angiotensin-converting enzyme inhibitors . Enrolled patients aged 12-18 years with at least 5
      years disease duration and HbA1c â‰¤8.5%. Patients were randomly assigned into two groups;
      intervention group who received vitamin B complex once daily orally . The other group did not
      receive any supplementation and served as a control group. Both groups were followed-up for
      12 weeks with assessment of plasma homocysteine, HbA1c, cystatin C and UAE.
    
  